Skip to main content

Knee Osteoarthritis (Knee OA)

1
Pipeline Programs
4
Companies
4
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Glaceum
GlaceumKorea - Suwon
1 program
1
VutiglabridinPhase 21 trial
Active Trials
NCT06845553Recruiting60Est. Dec 2026
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
Drain Removal Before CPMN/A1 trial
Active Trials
NCT07302724Active Not RecruitingEst. Dec 2025
Sanofi
SanofiPARIS, France
1 program
Kruskal-Wallis and qualitative parametersN/A1 trial
Active Trials
NCT01747759Completed44Est. Mar 2012
Next Science
Next ScienceAustralia - Sydney
1 program
genicular artery embolizationN/A1 trial
Active Trials
NCT06872567Recruiting126Est. Dec 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GlaceumVutiglabridin
Next Sciencegenicular artery embolization
City TherapeuticsDrain Removal Before CPM
SanofiKruskal-Wallis and qualitative parameters

Clinical Trials (4)

Total enrollment: 230 patients across 4 trials

NCT06845553GlaceumVutiglabridin

A Study to Assess the Efficacy and Safety of Vutiglabridin in Knee Osteoarthritis Patients

Start: Aug 2025Est. completion: Dec 202660 patients
Phase 2Recruiting
NCT06872567Next Sciencegenicular artery embolization

Randomized Controlled Study Evaluating Genicular Artery Embolization Against Intra-Articular Corticosteroid Knee Injection for Osteoarthritic Knee Pain

Start: Oct 2025Est. completion: Dec 2026126 patients
N/ARecruiting
NCT07302724City TherapeuticsDrain Removal Before CPM

Drain Removal Before Versus After CPM in Primary Total Knee Arthroplasty

Start: Jun 2025Est. completion: Dec 2025
N/AActive Not Recruiting
NCT01747759SanofiKruskal-Wallis and qualitative parameters

Evaluation of a Preoperative Education in Total Knee Arthroplasty

Start: Nov 2010Est. completion: Mar 201244 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 230 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.